Swissmedic Approves Extended Therapeutic Indication for Omvoh®

Swissmedic has announced an important update regarding the therapeutic scope of Omvoh®. The newly approved indication…

Safety Alert: Recall of NaCl B. Braun Infusion Solution Batch

Swissmedic has issued an announcement regarding the immediate recall of batch number 251347651 of NaCl B.…

Swissmedic Expands Therapeutic Indication for Palforzia®

Swissmedic, Switzerland’s agency for the authorization and supervision of therapeutic products, has announced an extension of…

Swissmedic Announces Authorization of Ayvakyt®: A Clinical Update

Swissmedic, the Swiss agency for therapeutic products, has announced the first regulatory authorization for Ayvakyt®. This…

Swissmedic Grants Initial Authorization for Wainzua®: Key Regulatory Update

Swissmedic, the Swiss agency responsible for licensing and monitoring therapeutic products, has announced the initial authorization…

Tamsulosin and Its Association with Intraoperative Floppy Iris Syndrome: Swissmedic Insights

Swissmedic has issued an important notice about the risks of intraoperative floppy iris syndrome (IFIS) among…

Swissmedic Updates on Veterinary Drug Reactions: Key Insights from 2024 Reports

The latest vigilance report from Swissmedic highlights significant findings regarding adverse reactions to veterinary medicinal products…

Swissmedic Advisory: Reduced Shelf Life for Lecigon (Carbidopa/Entacapone/Levodopa)

Swissmedic has issued a health professional communication regarding a change in the shelf life of Lecigon,…

Swissmedic Approves Initial Authorization for Sogroya®: Key Details for Regulatory Professionals

Swissmedic has announced the first authorization for Sogroya®, marking a significant regulatory development. The approval introduces…

Swissmedic Update: Revised EU Medical Device Regulations Explained

On October 21, 2025, Swissmedic announced updates to key sections related to EU legal acts for…